Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 6/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018034 | 0.95 | PAK1 (0.57) | PAK1AURKAMETKDRTEK | |
| SCHEMBL4024568 | 0.88 | PAK1 (0.68) | PAK1PDGFRBP2RX7MALT1MEN1 | |
| SCHEMBL4583078 | 0.87 | KDR (0.56) | PAK1AURKAMETKDRTEK | |
| SCHEMBL4020785 | 0.86 | PAK1 (0.66) | PAK1P2RX7MALT1MEN1KMT2A | |
| SCHEMBL4025750 | 0.86 | PAK1 (0.66) | PAK1P2RX7MEN1KMT2ASUV39H1 | |
| SCHEMBL4024515 | 0.86 | PAK1 (0.56) | PAK1AURKAMETKDRTEK | |
| SCHEMBL4019812 | 0.86 | PAK1 (0.58) | PAK1AURKAMETKDRTEK | |
| SCHEMBL4024042 | 0.85 | PAK1 (0.71) | PAK1P2RX7MALT1MEN1KMT2A | |
| SCHEMBL4024051 | 0.85 | PAK1 (0.57) | PAK1AURKAMETKDRTEK | |
| SCHEMBL4016410 | 0.85 | PAK1 (0.64) | PAK1PDGFRBP2RX7MALT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | claimed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | claimed |
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903038-A1 | N-(1-hetaryl-piperidin-4-yl)-(het)arylamide as EP2 receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125463-A1 | N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | PAK1 1977/4885AURKA 4835/4885MET 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.